
1. intern med. 2019 feb 15;58(4):477-485. doi: 10.2169/internalmedicine.1194-18.
epub 2018 oct 17.

no regional disparities sofosbuvir plus ribavirin therapy hcv genotype 2
infection tochigi prefecture vicinity.

hirosawa t(1), morimoto n(1), miura k(1), tahara t(2), murohisa t(3), okamura
y(4), sato t(5), numao n(6), imai m(7), tano s(8), murayama k(9), kurata h(10),
ozawa i(11), fukaya y(12), yoshizumi h(13), watanabe s(1), tsukui m(1), takaoka
y(1), nomoto h(1), isoda n(1), yamamoto h(1).

author information: 
(1)division gastroenterology, department medicine, jichi medical
university, japan.
(2)department gastroenterology, saiseikai utsunomiya hospital, japan.
(3)department gastroenterology, dokkyo medical university, japan.
(4)department gastroenterology, sano kousei general hospital, japan.
(5)department gastroenterology, nasu red cross hospital, japan.
(6)department gastroenterology, haga red cross hospital, japan.
(7)department gastroenterological surgery, utsunomiya memorial hospital,
japan.
(8)department gastroenterology, shin-oyama city hospital, japan.
(9)department gastroenterology, koga red cross hospital, japan.
(10)department gastroenterology, tochigi medical center shimotsuga, japan.
(11)department hepatobiliary surgery, tochigi cancer center, japan.
(12)department internal medicine, nasu minami hospital, japan.
(13)department internal medicine, kamitsuga general hospital, japan.

objective regional disparities observed outcomes interferon
(ifn)-based therapy chronic hepatitis c virus (hcv) infection japanese
nationwide study. however, whether regional disparities observed
in outcomes direct-acting antiviral drugs, including sofosbuvir (sof) plus
ribavirin (rbv) therapy, remains unclear. methods conducted multicenter
study assess efficacy sof plus rbv therapy hcv genotype 2 infection
in tochigi prefecture vicinity, ifn-based therapy yielded low 
sustained virologic response (svr) rate. addition, divided tochigi
prefecture six regions examine regional disparities svr. patients 
we enrolled patients chronic hcv genotype 2 infection. results 583
patients enrolled, 569 (97.6%) completed treatment, 566 (97.1%) also
complied post-treatment follow-up 12 weeks. overall svr12 rate was
96.1% per protocol 93.7% intention-to-treat analyses. marked
differences observed svr12 subjects â‰¥65 <65 years age.
although large gaps observed characteristics patients and
accessibility medical resources, significant difference the
svr12 rate among six regions tochigi prefecture. conclusion sof plus rbv
therapy effective hcv genotype 2 infection area ifn-based
therapy previously shown unsatisfactory results. addition, regional
disparities svr12 observed tochigi prefecture.

doi: 10.2169/internalmedicine.1194-18 
pmcid: pmc6421161
pmid: 30333396  [indexed medline]

